Application effect of different chemoradiotherapy regimens in patients with limited-stage small cell lung cancer
Objective To investigate the application effect of different chemoradiotherapy regimens in patients with limited-stage small cell lung cancer(SCLC).Method A total of 52 patients with limited-stage SCLC who underwent eto-poside+cisplatin(EP)regimen chemotherapy combined with thoracic stereotactic radiotherapy were selected and divided into synchronous chemoradiotherapy group(31 cases)and sequential chemoradiotherapy group(21 cases)according to different chemoradiotherapy regimens.Patients in the synchronous chemoradiotherapy group received radiotherapy and chemotherapy simultaneously.Patients in the sequential chemoradiotherapy group received radiotherapy with two days in-terval after chemotherapy.The clinical efficacy,tumor markers[carbohydrate antigen 125(CA125),carcinoembryonic an-tigen(CEA)],incidence of adverse reactions and survival were compared between the two groups.Result There were no significant differences in the total effective rate and total incidence of adverse reactions between the two groups(P>0.05).After treatment,the levels of CA125 and CEA in two groups were lower than those before treatment,the levels of CA125 and CEA in synchronous chemoradiotherapy group were lower than those in sequential chemoradiotherapy group,and the differences were statistically significant(P<0.05).The median survival time of patients in the synchronous chemo-radiotherapy group was 8 months,which was significantly longer than 7 months in the sequential chemoradiotherapy group,and the difference was statistically significant(P<0.01).Conclusion Synchronous chemoradiotherapy and se-quential chemoradiotherapy have the same efficacy and safety in the treatment of patients with limited-stage SCLC.How-ever,synchronous chemoradiotherapy can rapidly reduce the levels of tumor markers,effectively control tumor metasta-sis,and prolong the median survival time.
small cell lung cancersequential chemoradiotherapysynchronous chemoradiotherapy
NETL
NSTL
万方数据
